BioNTech to shutter three sites in Germany as no buyers emerge
The restructuring affects up to 1,860 jobs as BioNTech shifts COVID-19 vaccine production to Pfizer and targets annual savings of about $587 million.
- BioNTech will close its manufacturing sites in Marburg, Tübingen and Idar-Oberstein after failing to find buyers despite months of efforts.
- The closures are expected to affect up to 1,860 jobs as the company restructures its operations following the decline in demand for COVID-19 vaccines.
- BioNTech plans to shift vaccine production to its partner Pfizer while increasingly focusing its business on cancer treatments and other mRNA-based therapies.
- The company said it has been working with employee representatives on socially responsible measures, including additional redundancy packages for affected workers.
- The closures are scheduled to be completed by the end of 2028, with Tübingen expected to shut in late 2027, Marburg in early 2028 and Idar-Oberstein by the end of 2028.
111 Articles
111 Articles
Biontech closes three German plants – 1,800 jobs fall away. Tübingen's mayor Boris Palmer is outraged: a promise has been broken.
The months-long search for a buyer has failed and the German company BioNTech has decided to close three of its centers in Germany. These are the complexes in Idar-Oberstein, Marburg and Tübingen, where about 1,800 people work. BioNTech became one of the most well-known pharmaceutical companies during the pandemic, after developing one of the first vaccines against COVID-19 based on mRNA technology together with Pfizer. The vaccine brought the c…
The Mainz-based company closes three locations in Germany for which it has not found a buyer. It is now fully focused on drugs for cancer. The new path is full of obstacles.
Germany's BioNTech, which developed one of the most widely used COVID-19 vaccines with Pfizer during the pandemic, will close three locations in Germany. The company has been looking for buyers for them, but has not found them despite an extensive sales process. The closures are part of a broader restructuring of its production network, with which BioNTech is increasingly focusing on the development of cancer drugs after the decline in demand fo…
Coverage Details
Bias Distribution
- 47% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
